Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

Eli Lilly & Co. (NYSE:LLY) declared a quarterly dividend of $1.50 per share, or $6 annualized. The dividend will be payable on... Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome ...

Of Florida’s 30-member delegation, at least seven don’t own, buy or sell stocks, nor do their spouses or dependent children, ...

Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk board and Lars Fruergaard Jorgensen have jointly concluded that ...

Revenue and Earnings Per Share (EPS) are the heart of the fundamental analysis of a company's worth. The Revenue and EPS Summary provides the Revenue, EPS and Dividends of a company by year and ...

Also among its top holdings at the end of March were financial stocks JPMorgan Chase and Mastercard, valued at at $849 ...

Novo Nordisk rode Ozempic's success to becoming Europe's top company. Now it's faltering and its CEO is out. Novo Nordisk rode Ozempic's success to becoming Europe's top company. Now it's faltering ...